Gilead Sciences is working on easier-to-administer formulations of remdesivir for COVID-19 that could be used outside of hospitals, including ones that can be inhaled, as reported in Yahoo!News. The company also stated that it is looking at ways to use remdesivir earlier in the course of disease.
Company executives such as chief medical officer Merdad Parsey and chief financial officer Andrew Dickinson have said that in the longer term, Gilead is exploring a subcutaneous injection formulation of remdesivir, as well as dry powder versions to be inhaled.
According to the news source, remdesivir cannot be given as a pill because it has a chemical makeup that would degrade in the liver, and the intravenous (IV) formulation is only used by hospitals.
In the short term, Gilead is studying how its existing IV formulation of remdesivir can be diluted for use with a nebulizer to administer the medication in the form of a mist inhaled into the lungs.
"People look forward to an inhaled formulation in time," but development is in the very early stages, noted Jefferies analyst Michael Yee, adding that demand may be limited as many patients only need minimal treatment.
Yee also said Gilead is building up its capacity to supply remdesivir and has begun talking to governments around the world about commercial pricing.
To read more NewsPoints articles, click here.